These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 31480379)

  • 1. Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy.
    Schirrmacher V; van Gool S; Stuecker W
    Biomedicines; 2019 Aug; 7(3):. PubMed ID: 31480379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
    Schirrmacher V
    Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus.
    Schirrmacher V
    Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!
    Schirrmacher V
    Biomedicines; 2016 Jul; 4(3):. PubMed ID: 28536382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
    Vijayakumar G; Palese P; Goff PH
    EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
    Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy.
    Schirrmacher V; van Gool S; Stuecker W
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host.
    Fournier P; Schirrmacher V
    Biology (Basel); 2013 Jul; 2(3):936-75. PubMed ID: 24833054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients.
    Schirrmacher V
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28531117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy.
    Marek J; Hanesch L; Krabbe T; El Khawanky N; Heidegger S; Altomonte J
    Mol Ther Oncolytics; 2023 Sep; 30():117-131. PubMed ID: 37654972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
    Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
    J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newcastle disease virus (NDV): brief history of its oncolytic strains.
    Sinkovics JG; Horvath JC
    J Clin Virol; 2000 Feb; 16(1):1-15. PubMed ID: 10680736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and clinical usage of newcastle disease virus in cancer therapy.
    Lam HY; Yeap SK; Pirozyan MR; Omar AR; Yusoff K; Suraini AA; Abd-Aziz S; Alitheen NB
    J Biomed Biotechnol; 2011; 2011():718710. PubMed ID: 22131816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic Newcastle disease virus carrying the IL24 gene exerts antitumor effects by inhibiting tumor growth and vascular sprouting.
    Wu Q; Jin Y; Li S; Guo X; Sun W; Liu J; Li Q; Niu D; Zou Y; Du X; Li Y; Zhao T; Li Z; Li X; Ren G
    Int Immunopharmacol; 2024 Jul; 136():112305. PubMed ID: 38823178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution.
    Schirrmacher V; Van Gool S; Stuecker W
    Biomedicines; 2024 Mar; 12(4):. PubMed ID: 38672110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus.
    Meng Q; He J; Zhong L; Zhao Y
    Int J Med Sci; 2021; 18(11):2294-2302. PubMed ID: 33967605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
    Fournier P; Bian H; Szeberényi J; Schirrmacher V
    Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of oncolytic Newcastle disease virus: a critical review.
    Tayeb S; Zakay-Rones Z; Panet A
    Oncolytic Virother; 2015; 4():49-62. PubMed ID: 27512670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells.
    Shao X; Wang X; Guo X; Jiang K; Ye T; Chen J; Fang J; Gu L; Wang S; Zhang G; Meng S; Xu Q
    Front Oncol; 2019; 9():436. PubMed ID: 31192135
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells.
    Wang X; Shao X; Gu L; Jiang K; Wang S; Chen J; Fang J; Guo X; Yuan M; Shi J; Ding C; Meng S; Xu Q
    J Cell Mol Med; 2020 Apr; 24(7):4286-4297. PubMed ID: 32100392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.